Biotechnology

The obesity pipeline mainly consitsts of 1s5-3rd generation incretin combination therapies expected to decrease the BMI by 15, 17 and 22%, respectively. However, oral formulations and other drugs complementing the effect of GLP1 receptor agonists are coming up.
  1. Biotechnology

FDA approves globally first obesity pill

Novo Nordisk has once again made medical history. Following the success of injectable GLP-1 therapies for obesity and diabetes, the FDA has approved the first oral GLP-1 pill specifically for weight loss: Wegovy. While the oral semaglutide formulation Rybelsus has been available for type 2 diabetes, Wegovy as a pill represents the first FDA-approved oral […]
Written by
Advancements in Road Accident Prediction Models
  1. Biotechnology

Advancements in Road Accident Prediction Models

In a rapidly evolving world where transportation systems are integral to our daily lives, the safety of roadways remains a paramount concern. The intriguing new study conducted by Jia, Zhang, and Zhu delves into the complexities of road accidents, addressing the dire need for advanced analytical models that can predict and mitigate such occurrences effectively. […]
Written by
The best biotech movies to watch this winter holiday season
  1. Biotechnology

The best biotech movies to watch this winter holiday season

It’s the holiday season, and what’s better to do than cuddle up in bed and watch a movie? We want to make sure you’re not missing out on some binge-worthy biotech movies this December.   So, we have created a watchlist just for you. Here are some biotech movie recommendations to keep you entertained during the holidays!  The Andromeda Strain (1971)  Old but […]
Written by
Thanos Halazonetis, the scientific founder of FoRx from the University of Geneva
  1. Biotechnology

FoRx raises US$50m in Series A to advance PARG inhibitor

FoRx Therapeutics AG has closed a US$50m (CHF40m) Series A financing, in addition to its 2020 seed financing of US$10m. The Basel-based company develops precision oncology therapeutics. Funds advance Phase I development of lead candidate FORX-428. The round was insider-led and strategically oversubscribed. Existing investors supported the financing. They include EQT Life Sciences, Pfizer Ventures […]
Written by
  1. Biotechnology

Demand for Precise, Practical Neonatal Bilirubin Testing

Accurate and Actionable Neonatal Bilirubin Testing: A Critical Frontier in Newborn Care In the intricate landscape of neonatal medicine, the precision of bilirubin assays has emerged as a paramount concern that commands both clinical vigilance and laboratory excellence. Neonatal hyperbilirubinemia remains a widespread condition globally, implicating significant morbidity risks if not identified and managed with […]
Written by
The biggest biotech funding rounds in November 2025
  1. Biotechnology

The biggest biotech funding rounds in November 2025

The companies Cogent Biosciences, Braveheart Bio, and AAVantgarde bagged the biggest biotech funding rounds overall in November 2025 across private and public funding types. In this article, we break down last month’s private and public fundraising activity, looking at the largest rounds in more detail. Private biotech funding rounds in November 2025 First, let’s take […]
Written by

Good Reads

The traffic controller: GARLH4 dictates neuroligin synapse-type preference

Neuroligin isoforms are commonly thought to intrinsically specify synapse identity. In this issue, Yamasaki et al. (https://doi.org/10.1083/jcb.202507190) show that the auxiliary protein GARLH4 (LHFPL4) instead dictates neuroligin preference via competitive hierarchy, enabling dynamic reassignment between excitatory and inhibitory postsynaptic domains.
Written by

Worlwide

The traffic controller: GARLH4 dictates neuroligin synapse-type preference

Neuroligin isoforms are commonly thought to intrinsically specify synapse identity. In this issue, Yamasaki et al. (https://doi.org/10.1083/jcb.202507190) show that the auxiliary protein GARLH4 (LHFPL4) instead dictates neuroligin preference via competitive hierarchy, enabling dynamic reassignment between excitatory and inhibitory postsynaptic domains.
Written by

Trending

Login

Welcome to Life Science News!
"Explore the Latest Discoveries and Breakthroughs in Life Science with Life Science News!"
Read Smart, Save Time
Pick all the topics you are interested in to fill your homepage with stories you'll love.
Join our community
Registration is closed.